The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
## Table 0 ##
In the commercial group market, broad-based growth was across group sizes and regions, led by gains in services to small groups and resulted in the overall increase in people served through risk-based benefit plans.
Fee-based commercial group business declined due to the non-renewal of one public sector customer.
Membership in individual business decreased due to our reduced participation in ACA-compliant products in 2017.
Medicare Advantage increased year-over-year due to growth in people served through individual and employer-sponsored group Medicare Advantage plans.
Medicaid growth was driven by the combination of new state-based awards and growth in established programs.
Medicare Supplement growth reflected strong customer retention and new sales.
UnitedHealthcare’s revenue increase was due to growth in the number of individuals served across its businesses and price increases for underlying medical cost trends, which were partially offset by the reduction of people served in ACA-compliant individual products and the impact of the Health Insurance Industry Tax moratorium.
The increase in UnitedHealthcare’s earnings from operations was led by diversified growth and increased operating margin.
The 2016 results included losses in ACA-complaint individual products and guaranty fund assessments.
Optum Total revenues and earnings from operations increased as each segment reported increased revenues and earnings from operations as a result of the factors discussed below.
The results by segment were as follows: OptumHealth Revenue and earnings from operations increased at OptumHealth primarily due to organic and acquisition-related growth in care delivery
general corporate use), $28.4 billion of debt securities and $2.0 billion of investments in equity securities consisting of investments in non-U.
S.  dollar fixed-income funds; employee savings plan related investments; and dividend paying stocks.
Given the significant portion of our portfolio held in cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position.
Other sources of liquidity, primarily from operating cash flows and our commercial paper program, which is supported by our bank credit facilities, reduce the need to sell investments during adverse market conditions.
See Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements” for further detail concerning our fair value measurements.
Our available-for-sale debt portfolio had a weighted-average duration of 3.2 years and a weighted-average credit rating of “Double A” as of December 31, 2017.
When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
Capital Resources and Uses of Liquidity In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows: Commercial Paper and Bank Credit Facilities.
Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of senior unsecured debt through third-party broker-dealers, and are available for general corporate purposes.
For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements.
” Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 55%.
As of December 31, 2017, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 37%.
Long-Term Debt.
Periodically, we access capital markets to issue long-term debt for general corporate purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases.
For more information on our debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8 “Financial Statements.
” Credit Ratings.
Our credit ratings as of December 31, 2017 were as follows:
## Table 1 ##
(a) In January 2018, S&P Global affirmed our ratings and changed our outlook to Stable.
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions.
For example, a significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program.
As of December 31, 2017, we had Board authorization to purchase up to 42 million shares of our common stock.
For more information on our share repurchase program, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements.
” Dividends.
In June 2017, our Board increased our quarterly cash dividend to shareholders by 20% to an annual dividend rate of $3.00 per share.
For more information on our dividend, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements.
”
December 31, 2017 and 2016, respectively), the RSF associated with the AARP Program, accruals for premium rebate payments under the ACA, the current portion of future policy benefits and customer balances.
Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice.
Costs related to the acquisition and renewal of short duration customer contracts are charged to expense as incurred.
Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside the control of the Company are classified as temporary equity.
The following table provides details of the Company’s redeemable noncontrolling interests’ activity for the years ended December 31, 2017 and 2016:
## Table 2 ##
Share-Based Compensation The Company recognizes compensation expense for share-based awards, including stock options, stock-settled stock appreciation rights (SARs) and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier.
Restricted shares vest ratably, primarily over two to five years and compensation expense related to restricted shares is based on the share price on date of grant.
Stock options and SARs vest ratably primarily over four years and may be exercised up to 10 years from the date of grant.
Compensation expense related to stock options and SARs is based on the fair value at date of grant, which is estimated on the date of grant using a binomial option-pricing model.
Under the Company’s Employee Stock Purchase Plan (ESPP), eligible employees are allowed to purchase the Company’s stock at a discounted price, which is 85% of the lower market price of the Company’s common stock at the beginning or at the end of the six-month purchase period.
Share-based compensation expense for all programs is recognized in operating costs in the Consolidated Statements of Operations.
Net Earnings Per Common Share The Company computes basic earnings per common share attributable to UnitedHealth Group common shareholders by dividing net earnings attributable to UnitedHealth Group common shareholders by the weightedaverage number of common shares outstanding during the period.
The Company determines diluted net earnings per common share attributable to UnitedHealth Group common shareholders using the weighted-average number of common shares outstanding during the period, adjusted for potentially dilutive shares associated with stock options, SARs, restricted shares and the ESPP (collectively, common stock equivalents), using the treasury stock method.
The treasury stock method assumes a hypothetical issuance of shares to settle the share-based awards, with the assumed proceeds used to purchase common stock at the average market price for the period.
Assumed proceeds include the amount the employee must pay upon exercise and any unrecognized compensation cost.
The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS Union Pacific Corporation and Subsidiary Companies For purposes of this report, unless the context otherwise requires, all references herein to the “Corporation”, “UPC”, “we”, “us”, and “our” mean Union Pacific Corporation and its subsidiaries, including Union Pacific Railroad Company, which will be separately referred to herein as “UPRR” or the “Railroad”.1.
Nature of Operations Operations and Segmentation – We are a Class I railroad that operates in the United States.
We have 32,094 route miles, linking Pacific Coast and Gulf Coast ports with the Midwest and eastern United States gateways and providing several corridors to key Mexican gateways.
We serve the western twothirds of the country and maintain coordinated schedules with other rail carriers for the handling of freight to and from the Atlantic Coast, the Pacific Coast, the Southeast, the Southwest, Canada, and Mexico.
Export and import traffic is moved through Gulf Coast and Pacific Coast ports and across the Mexican and Canadian borders.
The Railroad, along with its subsidiaries and rail affiliates, is our one reportable operating segment.
Although revenues are analyzed by commodity group, we analyze the net financial results of the Railroad as one segment due to the integrated nature of our rail network.
The following table provides revenue by commodity group:
## Table 3 ##
Although our revenues are principally derived from customers domiciled in the United States, the ultimate points of origination or destination for some products transported are outside the United States.
Basis of Presentation – The Consolidated Financial Statements are presented in accordance with accounting principles generally accepted in the United States of America (GAAP) as codified in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC).
Subsequent Events Evaluation – We evaluated the effects of all subsequent events through February 5, 2010, the date of this report, which is concurrent with the date we file this report with the U. S.  Securities and Exchange Commission (SEC).2.
Significant Accounting Policies Change in Accounting Principle – We have historically accounted for rail grinding costs as a capital asset.
Beginning in the first quarter of 2010, we will change our accounting policy for rail grinding costs

Tables referenced above, in order (Table 0 first):
<table><tr><td></td><td colspan="3">December 31,</td><td colspan="2" rowspan="2"Change 2017 vs. 2016></td><td colspan="2" rowspan="2"Change 2016 vs. 2015></td></tr><tr><td>(in thousands, except percentages)</td><td>2017</td><td>2016</td><td>2015</td></tr><tr><td>Commercial risk-based - group</td><td>7,935</td><td>7,470</td><td>7,095</td><td>465</td><td>6%</td><td>375</td><td>5%</td></tr><tr><td>Commercial risk-based - individual</td><td>485</td><td>1,350</td><td>1,190</td><td>-865</td><td>-64</td><td>160</td><td>13</td></tr><tr><td>Commercial fee-based</td><td>18,595</td><td>18,900</td><td>18,565</td><td>-305</td><td>-2</td><td>335</td><td>2</td></tr><tr><td>Fee-based TRICARE</td><td>2,850</td><td>2,860</td><td>2,880</td><td>-10</td><td>—</td><td>-20</td><td>-1</td></tr><tr><td>Total commercial</td><td>29,865</td><td>30,580</td><td>29,730</td><td>-715</td><td>-2</td><td>850</td><td>3</td></tr><tr><td>Medicare Advantage</td><td>4,430</td><td>3,630</td><td>3,235</td><td>800</td><td>22</td><td>395</td><td>12</td></tr><tr><td>Medicaid</td><td>6,705</td><td>5,890</td><td>5,305</td><td>815</td><td>14</td><td>585</td><td>11</td></tr><tr><td>Medicare Supplement (Standardized)</td><td>4,445</td><td>4,265</td><td>4,035</td><td>180</td><td>4</td><td>230</td><td>6</td></tr><tr><td>Total public and senior</td><td>15,580</td><td>13,785</td><td>12,575</td><td>1,795</td><td>13</td><td>1,210</td><td>10</td></tr><tr><td>Total UnitedHealthcare - domestic medical</td><td>45,445</td><td>44,365</td><td>42,305</td><td>1,080</td><td>2</td><td>2,060</td><td>5</td></tr><tr><td>International</td><td>4,080</td><td>4,220</td><td>4,090</td><td>-140</td><td>-3</td><td>130</td><td>3</td></tr><tr><td>Total UnitedHealthcare - medical</td><td>49,525</td><td>48,585</td><td>46,395</td><td>940</td><td>2%</td><td>2,190</td><td>5%</td></tr><tr><td>Supplemental Data:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medicare Part D stand-alone</td><td>4,940</td><td>4,930</td><td>5,060</td><td>10</td><td>—%</td><td>-130</td><td>-3%</td></tr></table>
<table><tr><td></td><td colspan="2">Moody’s</td><td colspan="2">S&P Global</td><td colspan="2">Fitch</td><td colspan="2">A.M. Best</td></tr><tr><td></td><td>Ratings</td><td>Outlook</td><td>Ratings</td><td>Outlook</td><td>Ratings</td><td>Outlook</td><td>Ratings</td><td>Outlook</td></tr><tr><td>Senior unsecured debt</td><td>A3</td><td>Stable</td><td>A+</td><td>Negative<sup>(a)</sup></td><td>A-</td><td>Stable</td><td>bbb+</td><td>Stable</td></tr><tr><td>Commercial paper</td><td>P-2</td><td>n/a</td><td>A-1</td><td>n/a</td><td>F1</td><td>n/a</td><td>AMB-2</td><td>n/a</td></tr></table>
<table><tr><td>(in millions)</td><td>2017</td><td>2016</td></tr><tr><td>Redeemable noncontrolling interests, beginning of period</td><td>$2,012</td><td>$1,736</td></tr><tr><td>Net earnings</td><td>71</td><td>16</td></tr><tr><td>Acquisitions</td><td>565</td><td>34</td></tr><tr><td>Redemptions</td><td>-309</td><td>-123</td></tr><tr><td>Distributions</td><td>-38</td><td>-11</td></tr><tr><td>Fair value and other adjustments</td><td>-112</td><td>360</td></tr><tr><td>Redeemable noncontrolling interests, end of period</td><td>$2,189</td><td>$2,012</td></tr></table>
<table><tr><td><i>Millions of Dollars</i></td><td><i>2009</i></td><td><i>2008</i></td><td><i>2007</i></td></tr><tr><td>Agricultural</td><td>$2,666</td><td>$3,174</td><td>$2,605</td></tr><tr><td>Automotive</td><td>854</td><td>1,344</td><td>1,458</td></tr><tr><td>Chemicals</td><td>2,102</td><td>2,494</td><td>2,287</td></tr><tr><td>Energy</td><td>3,118</td><td>3,810</td><td>3,134</td></tr><tr><td>Industrial Products</td><td>2,147</td><td>3,273</td><td>3,077</td></tr><tr><td>Intermodal</td><td>2,486</td><td>3,023</td><td>2,925</td></tr><tr><td>Total freight revenues</td><td>$13,373</td><td>$17,118</td><td>$15,486</td></tr><tr><td>Other revenues</td><td>770</td><td>852</td><td>797</td></tr><tr><td>Total operating revenues</td><td>$14,143</td><td>$17,970</td><td>$16,283</td></tr></table>

Question: What's the sum of Industrial Products of 2009, and Medicare Advantage of December 31, 2016 ?
Answer: 5777
Reasoning program: add(2147.0,3630.0)